5 Oct 2026, 17:03
Securities Administration—
PERPERCHERON THERAPEUTICS LIMITED
Announcement history available from 1 August 2025
Fromto
5 Oct 2026, 08:24
Director Interests—
5 Oct 2026, 08:24
Director Interests—
5 Oct 2026, 08:21
Company Administration—
8 Sept 2026, 08:36
Securities Administration—
7 Sept 2026, 08:25
Securities Administration—
7 Sept 2026, 08:24
Meetings & Governance—
1 Sept 2026, 11:01
Presentations—
1 Sept 2026, 09:23
Securities Administration—
1 Sept 2026, 09:23
Securities Administration—
1 Sept 2026, 09:23
Securities Administration—
1 Sept 2026, 09:23
Capital RaisingMS
31 Aug 2026, 17:24
Director Interests—
31 Aug 2026, 17:22
Company Administration—
31 Aug 2026, 17:02
Director Interests—
31 Aug 2026, 17:01
Securities Administration—
31 Aug 2026, 12:06
Company Administration—
28 Aug 2026, 09:01
Trading Halt / SuspensionMS
28 Aug 2026, 08:11
Company UpdateMS
19 Aug 2026, 17:24
Financial ResultsMS
19 Aug 2026, 11:38
Company Administration—
19 Aug 2026, 11:33
Financial ResultsMS
14 Aug 2026, 14:46
Securities Administration—
12 Aug 2026, 08:16
Meetings & Governance—
10 Aug 2026, 08:24
Company AdministrationMS
31 July 2026, 08:29
Quarterly ReportsMS
3 July 2026, 16:21
Securities Administration—
17 June 2026, 08:22
Company Update—
2 June 2026, 08:22
Company Update—
1 June 2026, 15:41
Securities Administration—
29 May 2026, 11:26
Securities Administration—
26 May 2026, 09:22
Company Update—
1 May 2026, 08:15
Securities Administration—
30 Apr 2026, 08:57
Quarterly ReportsMS
22 Apr 2026, 09:20
Securities Administration—
22 Apr 2026, 09:17
Securities Administration—
21 Apr 2026, 08:17
Company Administration—
15 Apr 2026, 11:52
Securities Administration—
15 Apr 2026, 11:51
Securities Administration—
15 Apr 2026, 11:27
Securities Administration—
15 Apr 2026, 11:25
Securities Administration—
15 Apr 2026, 11:24
Director Interests—
15 Apr 2026, 11:18
Securities Administration—
15 Apr 2026, 11:10
Securities Administration—
14 Apr 2026, 13:00
Capital RaisingMS
2 Apr 2026, 09:47
Capital Raising—
31 Mar 2026, 08:22
Company Update—
24 Mar 2026, 08:18
Capital Raising—
24 Mar 2026, 08:18
Capital Raising—
24 Mar 2026, 08:17
Capital Raising—
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 5 Oct 2026, 17:03 | Proposed issue of securities - PER | Securities Administration | — | 06013 | |
| 5 Oct 2026, 08:24 | Final Director's Interest Notice | Director Interests | — | 02010 | |
| 5 Oct 2026, 08:24 | Initial Director's Interest Notice | Director Interests | — | 02008 | |
| 5 Oct 2026, 08:21 | Dr Michael Baker Commences as CEO and MD | Company Administration | — | 12008, 12019 | |
| 8 Sept 2026, 08:36 | Notice under S708A | Securities Administration | — | 06018 | |
| 7 Sept 2026, 08:25 | Application for quotation of securities - PER | Securities Administration | — | 06020 | |
| 7 Sept 2026, 08:24 | 2026 Notice of Annual General Meeting | Meetings & Governance | — | 08001, 08004 | |
| 1 Sept 2026, 11:01 | Percheron Therapeutics Limited Corporate Presentation | Presentations | — | 03026 | |
| 1 Sept 2026, 09:23 | Proposed issue of securities - PER | Securities Administration | — | 06013 | |
| 1 Sept 2026, 09:23 | Proposed issue of securities - PER | Securities Administration | — | 06013 | |
| 1 Sept 2026, 09:23 | Proposed issue of securities - PER | Securities Administration | — | 06013 | |
| 1 Sept 2026, 09:23 | Percheron raises $2.3m to fully fund clinical trial in AML | Capital Raising | MS | 06003, 06009, 08006, 09014 | |
| 31 Aug 2026, 17:24 | Initial Director's Interest Notice | Director Interests | — | 02008 | |
| 31 Aug 2026, 17:22 | Transitional appointment of Executive Director | Company Administration | — | 12001 | |
| 31 Aug 2026, 17:02 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 31 Aug 2026, 17:01 | Notification of cessation of securities - PER | Securities Administration | — | 06027 | |
| 31 Aug 2026, 12:06 | Percheron receives $0.70m R&D Tax Incentive Rebate | Company Administration | — | 12008 | |
| 28 Aug 2026, 09:01 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 28 Aug 2026, 08:11 | Vanderbilt Health to conduct clinical trial of HMBD-002 | Company Update | MS | 11001 | |
| 19 Aug 2026, 17:24 | Appendix 4E and Annual Report | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 19 Aug 2026, 11:38 | Appendix 4G and Corporate Governance Statement | Company Administration | — | 03024, 03025 | |
| 19 Aug 2026, 11:33 | Appendix 4E and Annual Report | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 14 Aug 2026, 14:46 | Application for quotation of securities - PER | Securities Administration | — | 06020 | |
| 12 Aug 2026, 08:16 | Notice of date of AGM and other relevant dates | Meetings & Governance | — | 08006 | |
| 10 Aug 2026, 08:24 | Percheron Therapeutics Announces CEO Succession | Company Administration | MS | 12019 | |
| 31 July 2026, 08:29 | Quarterly Activities Report and Appendix 4C | Quarterly Reports | MS | 19004, 19009 | |
| 3 July 2026, 16:21 | Notification regarding unquoted securities - PER | Securities Administration | — | 06021 | |
| 17 June 2026, 08:22 | Completion of HMBD-002 Drug Substance Manufacture | Company Update | — | 11001 | |
| 2 June 2026, 08:22 | New HMBD-002 Data Presented at ASCO Annual Meeting | Company Update | — | 11001 | |
| 1 June 2026, 15:41 | Notification regarding unquoted securities - PER | Securities Administration | — | 06021 | |
| 29 May 2026, 11:26 | Proposed issue of securities - PER | Securities Administration | — | 06013 | |
| 26 May 2026, 09:22 | WHO selects proposed INN for HMBD-002 | Company Update | — | 11001 | |
| 1 May 2026, 08:15 | Notification of cessation of securities - PER | Securities Administration | — | 06027 | |
| 30 Apr 2026, 08:57 | Quarterly Activities Report and Appendix 4C | Quarterly Reports | MS | 19003, 19008 | |
| 22 Apr 2026, 09:20 | Notification regarding unquoted securities - PER | Securities Administration | — | 06021 | |
| 22 Apr 2026, 09:17 | Application for quotation of securities - PER | Securities Administration | — | 06020 | |
| 21 Apr 2026, 08:17 | New HMBD-002 Data Presented at AACR Annual Meeting | Company Administration | — | 12008 | |
| 15 Apr 2026, 11:52 | Update - Notification regarding unquoted securities - PER | Securities Administration | — | 06021 | |
| 15 Apr 2026, 11:51 | Update - Notification regarding unquoted securities - PER | Securities Administration | — | 06021 | |
| 15 Apr 2026, 11:27 | Notification regarding unquoted securities - PER | Securities Administration | — | 06021 | |
| 15 Apr 2026, 11:25 | Notification regarding unquoted securities - PER | Securities Administration | — | 06021 | |
| 15 Apr 2026, 11:24 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 15 Apr 2026, 11:18 | Notification regarding unquoted securities - PER | Securities Administration | — | 06021 | |
| 15 Apr 2026, 11:10 | Application for quotation of securities - PER | Securities Administration | — | 06020 | |
| 14 Apr 2026, 13:00 | Results of Entitlement Offer | Capital Raising | MS | 06008 | |
| 2 Apr 2026, 09:47 | Non-renounceable Entitlement Offer Closing Date Reminder | Capital Raising | — | 06008 | |
| 31 Mar 2026, 08:22 | New HMBD-002 Preclinical Data to be Presented at ASCO | Company Update | — | 11001 | |
| 24 Mar 2026, 08:18 | Letter to Ineligible Shareholders | Capital Raising | — | 06008, 16002 | |
| 24 Mar 2026, 08:18 | Letter to Eligible Shareholders | Capital Raising | — | 06008, 16002 | |
| 24 Mar 2026, 08:17 | Non-renounceable Entitlement Offer Opens | Capital Raising | — | 06008 |
1–50 of 77
1 / 2